To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: AZD1305

• Registration Number: NCT00689247
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-04
• Primary Completion: 2008-05
• Study Completion: 2008-05
• Study First Submitted: 2008-05-30
• Study First Submitted QC: 2008-06-02
• Study First Posted: 2008-06-03
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-02
• Last Update Posted: 2010-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

• Healthy volunteers
• A body mass index (BMI=weight/height2) of 19 to 30 kg/m2

Read More

Exclusion Criteria

• Potassium outside normal reference values
• ECG findings outside normal range

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
A	AZD1305	AZD1305 given as oral solution
B	AZD1305	AZD1305 given as iv infusion

Primary Outcome Measures

Name	Time	Method
Pharmacokinetic variables	During all dosing visits

Secondary Outcome Measures

Name	Time	Method
Adverse events, vital signs, ECG, laboratory variables and physical examination	During the study

Trial Locations

Locations (1)

Research Site; 🇬🇧 Macclesfield, Cheshire, United Kingdom